SynthesisKidney3602026
The Role of Immune Cells as Modulators of Progression in Polycystic Kidney Disease: A Systematic Review.
Synthesis in Kidney360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A new conceptual framework for PKD1 in ADPKD; integrating DNA structures and inflammation.BMC nephrology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder caused by mutations in genes encoding ciliary proteins. Increasing evidence suggests that immune cell infiltration, chronic inflammation, and dysregulated immune signaling pathways contribute to cyst growth, fibrosis, and progressive kidney function decline. Notably, features of chronic inflammation are already detectable in early stages of the disease, including infiltration by immune cells, elevated levels of proinflammatory cytokines, and immunologic crosstalk between immune and epithelial cells. These immune responses promote fibroblast activation and excessive extracellular matrix deposition through key signaling pathways such as NF kappa-light-chain-enhancer of activated B cells, Janus kinases-signal transducers and activators of transcription, and TGF β -small mothers against decapentaplegic, ultimately driving renal fibrosis and functional deterioration. Conversely, components of the adaptive immune system have been implicated in slowing disease progression. CD8 +T cells have been shown to exert a protective effect by limiting cyst expansion and preserving tubular architecture. Remarkably, cyst-lining epithelial cells themselves can regulate immune cell activity, highlighting a complex and dynamic interplay between ADPKD and the immune system at multiple levels. Beyond direct crosstalk, immune mechanisms may also contribute to the genotype-independent interindividual variability observed in ADPKD progression. In this review, we provide a comprehensive overview on the role of immune cells in ADPKD, offering mechanistic insight into the processes underlying cyst initiation and progression. This perspective underscores the increasing recognition that cystic kidneys share fundamental features with tumor-like microenvironments, including chronic inflammation, immune-driven matrix remodeling, and metabolic dysregulation. We further summarize emerging immune-related biomarkers and therapeutic targets, providing a foundation for future translational approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.